 Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Efficacy and safety of pembrolizumab combined with cetuximab in the treatment of relapsed/metastatic HNSCC

Lancet oncol: Efficacy and safety of pembrolizumab combined with cetuximab in the treatment of relapsed/metastatic HNSCC

 Last Update: 2021-05-21
 Source: Internet
 Author: User

Tags

guanfacine 2 mg

1 4 ferrule

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) as a single agent and combined cytotoxic chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have shown treatment active.

This is an open-label, non-randomized, multi-arm Phase 2 trial conducted in 4 academic centers in the USA, recruiting platinum-tolerant or platinum-inapplicable recurrent or metastatic HNSCCs over 18 years of age Patients, and require no previous immunotherapy or EGFR suppression therapy.

immunity

Optimal remission

From March 22, 2017 to July 16, 2019, a total of 33 test patients were recruited in cohort 1.

At the 6th month, the overall response rate was 45% (95% CI 28-62)

Progression-free survival and overall survival

The most common grade 3-4 treatment-related adverse events were oral mucositis (9%, 3/33), and 5 patients (15%) had serious treatment-related adverse events.

Treatment-related adverse events

All in all, pembrolizumab combined with cetuximab has shown promising clinical activity in patients with recurrent or metastatic head and neck squamous cell carcinoma , which is worthy of further study.

Pembrolizumab combined with cetuximab showed promising clinical activity in patients with recurrent or metastatic head and neck squamous cell carcinoma

Original source:

Assuntina G Sacco, et al.

org/10.
1016/S1470-2045(21)00136-4" target="_blank" rel="noopener">embrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.